Seqens Seqens

X

Find the latest Drugs in Development and Pipeline Prospector News of Allergy Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Allergy Therapeutics
unitedkingdom_new Flag
Country
Country
United Kingdom
Address
Address
Allergy Therapeutics, Dominion Way, Worthing, West Sussex, BN14 8SA, United Kingdom
Telephone
Telephone
44 190 384 5849
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.


Lead Product(s): VLP Peanut

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: IND EnablingProduct Type: Vaccine

Partner/Sponsor/Collaborator: AGC Biologics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership March 31, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.


Lead Product(s): VLP-Based Peanut Allergy Vaccine

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: IND EnablingProduct Type: Vaccine

Recipient: AGC Biologics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership March 31, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Allergy Therapeutics announces start of key exploratory field study in advance of pivotal Phase III Grass trial;Breakthrough study design to deliver for the first time cutting edge scientific concepts in the Allergy field to optimize SCIT trial results.


Lead Product(s): Grass MATA MPL

Therapeutic Area: Immunology Product Name: Grass MATA MPL

Highest Development Status: Phase IIIProduct Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 26, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Technical issues in the study made it difficult to reconstruct the primary endpoint data and the PEI agreed that B301 cannot be considered for assessment of clinical efficacy and a new pivotal Phase III study will be conducted within the therapy allergens ordinance time frame.


Lead Product(s): Tree MATA MPL

Therapeutic Area: Immunology Product Name: Tree MATA MPL

Highest Development Status: Phase IIIProduct Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 09, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY